Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.

Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases.

Immunic, Inc. is headquartered in New York, New York.